Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ( " Ensysce " or the " Company " ) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced receipt of notice...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials